SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure after Q3 results highlighted weaker trading activity, with headline profit largely driven by gains on crypto holdings; the Binance hack and broader crypto weakness added to selling pressure. Traders are split between viewing the decline as a buying opportunity and worrying that soft volumes and shaken confidence in exchanges could prolong the downturn.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and the company raised its full-year delivery outlook as the R2 ramp gained traction, driving bullish discussion about improving execution and future growth. Traders remain divided, with some expecting a recovery while others point to continued cash burn and a muted share-price reaction.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Bank of America upgrade, citing DraftKings Predictions exchange as a potential growth opportunity, has fueled rebound interest after a steep selloff. Traders remain divided over whether rising exchange activity can offset regulatory uncertainty, competition from Kalshi and Polymarket, and pressure on the sportsbook business.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its 80-event milestone, which starts database lock, unblinding and final analysis, is drawing attention ahead of the expected topline results. Bulls point to the trials long duration and extended GPS dosing as possible signs of durable survival benefit, while skeptics question the dosing changes and trial design; the share-price decline has added to the debate.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Biotechs sector-wide swings and rotation are driving attention, with traders weighing weakness tied to rising-rate concerns and money moving between biotech and tech against hopes for renewed inflows and M&A. The debate is whether the pullback is a deeper correction or a buying opportunity, with XBIs support levels and upcoming biotech catalysts in focus.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Cornings quarterly earnings beat and upbeat outlook, driven by AI-related optical communications demand, are being weighed against a sharp share-price pullback and bearish chart signals. Traders are split between viewing the decline as an overreaction to strong results and pointing to put-heavy options activity and broken support as signs of further near-term pressure.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

XLP is drawing attention as investors rotate toward defensive consumer staples amid weakness in technology and AI-related stocks, with traders highlighting the funds rebound toward record highs. The rally has prompted bullish technical commentary, while others caution that staples look stretched and the defensive trade may be crowded.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high has focused attention on TGTX, with traders weighing BRIUMVIs sales momentum and Q3 results against anticipated subcutaneous BRIUMVI data. Buyout speculation and possible short covering are also prominent, but no acquisition is confirmed.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,715,255,345.65554501 with 589,238,256,711,817.89342663 in circulation. The last known price of Shiba Inu is 0.00000467 USD and is down -2.68 over the last 24 hours. It is currently trading on 1123 active market(s) with $35,462,996.64 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention for choppy, largely range-bound trading, with repeated technical-chart posts describing consolidation and traders debating whether it can break resistance or resume falling. Long-term holders are buying dips and hoping for a meme-coin rally, while skeptics cite weak utility, token burns that have not shifted sentiment, and prolonged underperformance.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is under pressure amid a broader crypto and AI data-center selloff, with traders especially focused on its reliance on CoreWeave as Helioss tenant and the lack of a new tenant announcement. Some see the strong quarterly results, buyback authorization, and data-center growth as support, while others worry about customer concentration, financing risks, and management credibility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.

Viking Therapeutics Stock Jumps: What's Going On?

Viking Therapeutics Inc (NASDAQ:VKTX) shares are popping Thursday. The obesity drug developer reported third-quarter results that paired a wider-than-expected loss with positive study data and a $960 million cash balance.read more...

LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised

Lilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.

VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.

VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail

Equity

CEO Brian Lian said a potential launch of obesity drug VK2735 remained about 2 and a half years away.

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireSAN DIEGO, Oct. 28, 2026 --VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to...

Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings

Lilly heads into Q3 earnings with Mounjaro, Zepbound and new drugs fueling growth, but pricing pressure, rising costs and competition pose challenges.

Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?

VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.

Reported GAAP EPS of -$1.55 down -91.36% YoY

Viking Therapeutics reported a $183.2M Q3 2026 net loss, disclosed clinical-development risks including failure to replicate prior results, and had no revenue alongside common-stock and convertible-note financing.

Viking Therapeutics reported VK2735 weight-loss maintenance across less-frequent dosing, initiated oral VK2735 Phase 3 trials alongside subcutaneous studies, and ended Q3 2026 with $960M in cash.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Viking reported a $1.55 per share loss, versus the $1.06 loss analysts expected.</li><li>The company held $960 million in cash and investments, with average quarterly cash usage projected around $100 million.</li><li>Four Phase 3 trials are underway across injectable and oral versions of VK2735.</li></ul>Shares of Viking Therapeutics (VKTX) fell nearly 3% overnight late Wednesday after posting a wider-than-expected quarterly loss, while CEO Brian Lian’s outlook for an obesity-drug launch more than two years away also sparked retail backlash.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> rose nearly 2% to $25.36 on Wednesday, bringing its weekly gain to about 4% and putting it on track to end a four-week losing streak.&nbsp;<h2 class="st-heading-2">VKTX Launch Outlook Tests Investor Patience</h2>Lian’s timeline came during a discussion of commercial preparations for VK2735, Viking’s experimental obesity treatment targeting the GLP-1 and GIP receptors. “We have a pretty solid commercial team, especially given that we're 2 and a half years out from potential launch,” he said on Wednesday’s earnings call.Viking is developing both injectable and tablet versions of VK2735 as it seeks to compete in an obesity-treatment market led by Eli Lilly and Novo Nordisk.&nbsp;Lian said Viking has hired leaders in commercial operations, market access and medical affairs, and added staff in supply chain, technical operations, quality and compliance.<h2 class="st-heading-2">VKTX Q3 Review</h2>Viking reported a third-quarter (Q3) loss of $1.55 per share, compared with the $1.06 loss analysts expected. Net loss more than doubled to $183.2 million from $90.8 million a year earlier.Research and development expenses rose to $166.8 million from $90 million as trial and manufacturing costs increased. General and administrative expenses climbed to $20.3 million from $8.6 million.Viking ended September with $960 million in cash, equivalents and short-term investments, up from $706 million at year-end. Stock and convertible-note offerings raised about $575 million before expenses during the quarter.“But I think as we think about cash, just company-wide, I think we'd see a usage of average of around $100 million per quarter,” CFO Greg Zante said. “But some quarters will be higher, some will be lower moving forward.”<h2 class="st-heading-2">Viking Bets On Pills And Monthly Shots</h2>Viking has four Phase 3 trials underway. Both injectable Vanquish trials are fully enrolled and on track, with the first patients expected to enter extension studies in early 2027. The oral Sunrise program began earlier this month. “If successful, we believe these studies will position VK2735 as the first oral formulation of a dual GLP-1/GIP agonist to reach the market,” Lian said.When asked about tablet doses, he said Viking wanted fewer and smaller pills while protecting margins. “We also want to make sure that the program makes economic sense. We need to have sufficient gross margins to allow us to run a highly profitable enterprise,” he said.Less-frequent treatment is another part of Viking’s pitch. After 21 weeks of weekly injections in its earlier maintenance study, patients switched to every-other-week dosing retained 83%-97% of their initial weight loss over the next 12 weeks. Monthly cohorts retained 82%-90%, versus 61% for patients switched to placebo.However, a label for less-frequent dosing may come later, supported by the larger Vanquish extension studies. “But it seems more likely that the VANQUISH extension data would be sort of a standalone package that would be a supplement later. But again, too early to say definitively,” Lian said.A second maintenance study, including a switch from injections to daily tablets, is expected to report results in 2027. Viking also plans to start a 28-day multiple-dose study of its amylin drug VK3019 in the first quarter of 2027.<h2 class="st-heading-2">How Do Retail Traders Feel About VKTX?</h2>On Stocktwits, retail sentiment for VKTX improved to ‘neutral’ from ‘bearish’ levels a day ago amid a 163% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_02601026af.png" alt="vktx ss.png" width="636" height="332"><figcaption>VKTX sentiment and message volume as of October 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/parrotineum/message/667600661">said</a>, “2.5 more years until commercialization? Plenty of time to find a new CEO then.” Another user&nbsp;<a href="https://stocktwits.com/Mark7531/message/667591399">said</a>, “Again bullish on drug bearish on BL [CEO Brian Lian].”A separate user&nbsp;<a href="https://stocktwits.com/giannis93giannis/message/667592018">said</a>, “I think its becoming more and more obvious that he is going to GIA and definitely not sell completely.” Others&nbsp;<a href="https://stocktwits.com/Georgejj/message/667602309">defended</a> its progress: “The company's conference call was GREAT. The trials are all proceeding as expected.”VKTX stock has declined 28% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-iova-stock-jump-after-hours-today/cZUQPNZR9Gr">Why Did IOVA Stock Jump Over 10% After-Hours Today?&nbsp;</a>

 In this photo illustration, the Viking Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are actively debating a potential high-premium acquisition, bolstered by aggressive market expansion comments from industry giants.

Massive daily volume indicates significant institutional buying and aggressive short-covering following recent sector-wide growth.

Retail investors and analysts are crunching numbers to compare potential future market caps against industry benchmarks.

Anticipation for the oral drug's success in trials is building as investors see it as a key competitive advantage in weight loss treatments.

Current Price	$27.28
Prev Close	$26.86
Open	$26.77
Dividend Yield	0.00%
50-Day Moving Average	$30.51
Beta	1.67
Avg. Volume	7.34M
PE Ratio	-5.05

52-Week High	$43.15
52-Week Low	$23.82
Market Capitalization	$3.48B
EPS (Annual)	-$3.19
Price to Book	5.91
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

VKTX Fundamentals